| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Gregory J Quirk | |
| Andrew Holmes | |||
| P2860 | cites work | Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta | Q24338360 |
| Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2C) receptor antagonist | Q24684698 | ||
| Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs | Q28209414 | ||
| Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice | Q28265467 | ||
| Prefrontal involvement in the regulation of emotion: convergence of rat and human studies | Q28272307 | ||
| Mechanisms of fear extinction | Q28278209 | ||
| Yohimbine use in a natural setting: effects on posttraumatic stress disorder | Q28370340 | ||
| Neural mechanisms of extinction learning and retrieval | Q29616240 | ||
| Memory--a century of consolidation | Q29618665 | ||
| Impaired Pavlovian fear extinction is a common phenotype across genetic lineages of the 129 inbred mouse strain | Q30478858 | ||
| The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats | Q30481352 | ||
| Context, ambiguity, and unlearning: sources of relapse after behavioral extinction | Q34159550 | ||
| Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors | Q34366950 | ||
| Gene-environment interactions in psychiatry: joining forces with neuroscience | Q34540742 | ||
| The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis | Q34663662 | ||
| Genetics of emotional regulation: the role of the serotonin transporter in neural function | Q36418581 | ||
| Psychosocial therapy for posttraumatic stress disorder. | Q36443872 | ||
| Effects of a new antidepressant drug on active avoidance behavior in rats. Comparative study with tricyclic antidepressants. | Q52278957 | ||
| YOHIMBINE FOR ERECTILE DYSFUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS | Q57942829 | ||
| Antidopaminergic properties of yohimbine | Q70655668 | ||
| Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs | Q72664427 | ||
| Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors | Q77337812 | ||
| ??? | Q28378094 | ||
| Effects of D-cycloserine on extinction: translation from preclinical to clinical work | Q36571171 | ||
| Effects of repeated maternal separation on anxiety- and depression-related phenotypes in different mouse strains | Q36584711 | ||
| A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders | Q36849248 | ||
| Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain | Q36900603 | ||
| Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice | Q36952517 | ||
| Response variation following trauma: a translational neuroscience approach to understanding PTSD. | Q36962671 | ||
| Yohimbine impairs extinction of cocaine-conditioned place preference in an alpha2-adrenergic receptor independent process | Q37077132 | ||
| The effects of yohimbine and amphetamine on fear expression and extinction in rats. | Q37217230 | ||
| Systemic propranolol acts centrally to reduce conditioned fear in rats without impairing extinction | Q37226023 | ||
| Impaired extinction of learned fear in rats selectively bred for high anxiety--evidence of altered neuronal processing in prefrontal-amygdala pathways | Q37420763 | ||
| Contextual control of the extinction of conditioned fear: tests for the associative value of the context | Q38579858 | ||
| Noradrenergic agonists and antagonists: Effects on conditioned fear as measured by the potentiated startle paradigm | Q39701846 | ||
| Adrenergic transmission facilitates extinction of conditional fear in mice. | Q40727513 | ||
| Noradrenergic mechanisms in stress and anxiety: II. Clinical studies | Q41045442 | ||
| Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks | Q41372084 | ||
| Noradrenaline, fear and extinction | Q41485675 | ||
| Serotonin 5-HT1D receptors in human prefrontal cortex and caudate: interaction with a GTP binding protein. | Q42209179 | ||
| Pharmacological characterisation of [35S]-GTPgammaS binding to Chinese hamster ovary cell membranes stably expressing cloned human 5-HT1D receptor subtypes | Q42526623 | ||
| Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice | Q42673666 | ||
| Behavioral reactivity to stress: amplification of stress-induced noradrenergic activation elicits a galanin-mediated anxiolytic effect in central amygdala. | Q43878256 | ||
| Characterization of hippocampal norepinephrine release as measured by microdialysis perfusion: pharmacological and behavioral studies | Q44196375 | ||
| Temporally massed CS presentations generate more fear extinction than spaced presentations | Q44504785 | ||
| Learning not to fear, faster | Q44822129 | ||
| Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. | Q44877807 | ||
| Discriminative stimulus properties of 8-OH-DPAT: relationship to affinity for 5HT1A receptors | Q45123102 | ||
| Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination | Q45124800 | ||
| Yohimbine disrupts prepulse inhibition in rats via action at 5-HT1A receptors, not alpha2-adrenoceptors | Q45272332 | ||
| Stress-induced enhancement of fear learning: an animal model of posttraumatic stress disorder. | Q45941038 | ||
| 5-HT1 receptor binding sites in the guinea pig superior colliculus are predominantly of the 5-HT1D class and are presynaptically located on primary retinal afferents | Q46549533 | ||
| Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction | Q46815741 | ||
| Chronic stress impairs recall of extinction of conditioned fear | Q46842404 | ||
| Prevention by 5-HT1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat. | Q48223818 | ||
| Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice | Q48305611 | ||
| Antagonism of the stimulus effects of yohimbine and 8-hydroxydipropylaminotetralin | Q48313680 | ||
| The psychobiology and psychopharmacology of PTSD. | Q48458642 | ||
| Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release | Q48491787 | ||
| Brief uncontrollable stress causes dendritic retraction in infralimbic cortex and resistance to fear extinction in mice. | Q48523175 | ||
| Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats | Q48578331 | ||
| The alpha 2-adrenoceptor antagonist idazoxan is an agonist at 5-HT1A autoreceptors modulating serotonin synthesis in the rat brain in vivo | Q48874361 | ||
| Locus coeruleus lesions and resistance to extinction of a classically conditioned response: involvement of the neocortex and hippocampus | Q48910833 | ||
| α 2 -Adrenoceptor-Mediated Hyperpolarization of Locus Coeruleus Neurons: Intracellular Studies in Vivo | Q48966785 | ||
| The effect of yohimbine on the extinction of conditioned fear: a role for context. | Q50896509 | ||
| D-cycloserine facilitates extinction but does not eliminate renewal of the conditioned emotional response. | Q50923411 | ||
| The dopaminergic modulation of fear: quinpirole impairs the recall of emotional memories in rats. | Q51090913 | ||
| Anxiolytic-like effects of yohimbine in the murine plus-maze: strain independence and evidence against alpha 2-adrenoceptor mediation. | Q51125505 | ||
| Emotional processing of fear: exposure to corrective information. | Q51217642 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 2-7 | |
| P577 | publication date | 2009-12-28 | |
| P1433 | published in | Trends in Pharmacological Sciences | Q2451474 |
| P1476 | title | Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine | |
| P478 | volume | 31 |
| Q28297569 | 50 years of hurdles and hope in anxiolytic drug discovery |
| Q41850830 | Alterations in neuronal morphology in infralimbic cortex predict resistance to fear extinction following acute stress. |
| Q48651417 | Attenuating the persistence of fear memory storage using a single dose of antidepressant |
| Q30410131 | Can fear extinction be enhanced? A review of pharmacological and behavioral findings |
| Q36243660 | Cannabinoid facilitation of fear extinction memory recall in humans |
| Q35043125 | Cognitive enhancers for anxiety disorders |
| Q36546326 | Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity |
| Q34505174 | Deepened extinction following compound stimulus presentation: noradrenergic modulation. |
| Q50635830 | Different fear states engage distinct networks within the intercalated cell clusters of the amygdala. |
| Q43909249 | Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial |
| Q34180554 | Effects of psychotropic agents on extinction of lever-press avoidance in a rat model of anxiety vulnerability. |
| Q34269011 | Enhanced extinction of aversive memories by high-frequency stimulation of the rat infralimbic cortex |
| Q34017493 | Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder |
| Q30394729 | Epigenetics and memory: causes, consequences and treatments for post-traumatic stress disorder and addiction |
| Q41967620 | Fear erasure in mice requires synergy between antidepressant drugs and extinction training. |
| Q37172922 | Fear extinction deficits following acute stress associate with increased spine density and dendritic retraction in basolateral amygdala neurons. |
| Q27310769 | Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids |
| Q35892774 | Genetic strain differences in learned fear inhibition associated with variation in neuroendocrine, autonomic, and amygdala dendritic phenotypes. |
| Q27310813 | Hunger Promotes Fear Extinction by Activation of an Amygdala Microcircuit. |
| Q28389310 | Individual differences in recovery from traumatic fear |
| Q35036750 | Is an epigenetic switch the key to persistent extinction? |
| Q39734497 | Low Doses of Allyphenyline and Cyclomethyline, Effective against Morphine Dependence, Elicit an Antidepressant-like Effect. |
| Q28396555 | Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders |
| Q64240028 | Neurochemical and molecular mechanisms underlying the retrieval-extinction effect |
| Q35985350 | Neuroenhancement of Exposure Therapy in Anxiety Disorders |
| Q34181201 | New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats |
| Q55092559 | Noradrenergic Modulation of Fear Conditioning and Extinction. |
| Q45331715 | Noradrenergic interactions via autonomic nervous system: a promising target for extinction-based exposure therapy? |
| Q36941269 | Pancreatic polypeptide and its central Y4 receptors are essential for cued fear extinction and permanent suppression of fear |
| Q30462825 | Pharmacological enhancement of fear reduction: preclinical models. |
| Q24633256 | Pharmacological treatment of PTSD - established and new approaches |
| Q26851461 | Pharmacological treatment of anxiety disorders: current treatments and future directions |
| Q27006437 | Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders |
| Q37110576 | Phosphoproteomic Analysis Reveals a Novel Mechanism of CaMKIIα Regulation Inversely Induced by Cocaine Memory Extinction versus Reconsolidation |
| Q48352646 | Postnatal transplantation of interneuronal precursor cells decreases anxiety-like behavior in adult mice |
| Q37698844 | Prazosin differentially affects extinction of cocaine conditioned place preference on the basis of dose and initial preference |
| Q37656934 | Prefrontal Dopaminergic Mechanisms of Extinction in Adolescence Compared to Adulthood in Rats. |
| Q33594739 | Prefrontal single-unit firing associated with deficient extinction in mice. |
| Q35146447 | Rescue of impaired fear extinction and normalization of cortico-amygdala circuit dysfunction in a genetic mouse model by dietary zinc restriction |
| Q30466738 | Seeking a spotless mind: extinction, deconsolidation, and erasure of fear memory |
| Q30366954 | Stress and Fear Extinction. |
| Q37053613 | Temporal factors in the extinction of fear in inbred mouse strains differing in extinction efficacy. |
| Q30426498 | The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders |
| Q34720448 | The influence of acute stress on the regulation of conditioned fear |
| Q46052162 | Winter day lengths counteract stimulatory effects of apomorphine and yohimbine on sexual behavior of male Syrian hamsters. |
Search more.